"10.1371_journal.pone.0083830","plos one","2013-12-23T00:00:00Z","Stefania Fiorcari; Wells S Brown; Bradley W McIntyre; Zeev Estrov; Rossana Maffei; Susan Oâ€™Brien; Mariela Sivina; Julia Hoellenriegel; William G Wierda; Michael J Keating; Wei Ding; Neil E Kay; Brian J Lannutti; Roberto Marasca; Jan A Burger","Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States of America; Gilead Sciences, Inc. Seattle, Washington, United States of America; Hematology Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy","Conceived and designed the experiments: SF JAB. Performed the experiments: SF WSB BWM. Analyzed the data: SF JAB. Contributed reagents/materials/analysis tools: WD NEK. Wrote the manuscript: SF JAB. Assisted with the experimental design, interpretation of the data, and reviewed the manuscript: ZE RM SO MS JH WGW MJK BJL RM.","J.B. and S.O.B. have received research funding from Gilead. B.J.L. is an employee of Gilead. The PI3K inhibitor idelalisib was provided by Gilead. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","12","Stefania Fiorcari","SF",15,TRUE,2,3,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
